ong-term visual and anatomic outcome of intravitreal injection of ranibizumab for myopic choroidal neovascularizatio
Not Applicable
- Conditions
- myopic choroidal neovascularization
- Registration Number
- JPRN-UMIN000020177
- Lead Sponsor
- Ophthalmology of Tokyo Medical and Dental University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 51
Inclusion Criteria
Not provided
Exclusion Criteria
1) a history of other treatments for myopic CNV (PDT, other anti-VEGF reagents than ranibizumab) 2) a history of vitreoretinal surgery 3) a presence of other ocular complications which could affect the vision (dense cataract, foveal retinal detachment, macular holes, etc.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The change of the best collected visual acuity(BCVA) at 2 years after IVR compared to the baseline in patients with myopic CNV.
- Secondary Outcome Measures
Name Time Method